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Introduction {#sec006}
============

Vancomycin, a glycopeptide antibiotic, was developed and released in the 1950s for the treatment of aerobic gram-positive infections and has been widely used primarily in the treatment of methicillin-resistant *Staphylococcus aureus* (MRSA) infections\[[@pone.0146224.ref001]\]. In recent years, MRSA has spread globally, and the incidence of MRSA has shown a rising trend. Meanwhile, concerns have been raised about inadequate responses to vancomycin if the minimum inhibitory concentration (MIC) of the infecting organism lies at the upper end of the susceptible range\[[@pone.0146224.ref002]\]. Thus, there is a growing need for monitoring vancomycin levels, evaluating the relationship between its clinical effectiveness and pharmacokinetic parameters, and developing an individualized dosing regimen\[[@pone.0146224.ref003]\].

Vancomycin appears to follow time-dependent killing\[[@pone.0146224.ref004]\]. *In vitro* tests and limited human trials have shown that the ratio of the 24-hour area under the concentration-time curve and MIC (AUC~0-24~/ MIC) of vancomycin is the pharmacokinetic/pharmacodynamics (PK/PD) parameter that is most relevant to its clinical effectiveness in the treatment of *Staphylococcus aureus* infections\[[@pone.0146224.ref005],[@pone.0146224.ref006]\]. An AUC~0-24~/MIC ratio higher than 400 is regarded as the target of clinical success. However, this conclusion was based on only one clinical observational study, which used the broth microdilution (BMD) method to test MIC, and had not been confirmedby performing a systematic review. Moreover, little was known regarding to what extent achieving high AUC~0-24~/MIC levels of vancomycin could enhance its clinical effectiveness. Thus, we performed a systematic review and meta-analysis to study these issues.

Methods {#sec007}
=======

Search strategy {#sec008}
---------------

Previously published articles and conference abstracts (until Jan 16, 2014) reporting the association between the AUC~0-24~/MIC ratio of vancomycin and its clinical effectiveness were identified by computerized literature searches in PubMed, Embase, the Web of Science, the Cochrane Library and two Chinese literature databases (CNKI and CBM). Reference lists of the retrieved articles and supplemental materials were also examined manually to further identify potentially relevant studies. The search term was "vancomycin". No restriction on language was applied. This study was a part of the development of Chinese practice guideline for therapeutic drug monitoring (TDM) of vancomycin launched by the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society.

Selection criteria {#sec009}
------------------

The literature was divided into eight parts whose eligibility was assessed according to titles and abstracts by eight separate groups based on PICOs relating to the development of Chinese practice guideline for vancomycin TDM (See [S1 File](#pone.0146224.s002){ref-type="supplementary-material"} for details). Each group consisted of two independent assessors. Results of the assessment were converged as a whole.

Furthermore, two authors (PM and HBL) independently searched the literature and examined the relevant studies for further assessment of the data. Each reviewer was blinded to the other reviewer during the process of data extraction. In cases of disagreement between the two reviewers, a third author (SDZ) was consulted. Both randomized controlled trials (RCTs) and observational studies were eligible with the following inclusion criteria: 1) comparing clinical effectiveness of high and low AUC~0-24~/MIC levels of vancomycin monotherapy; 2) breakpoints of the AUC~0-24~/MIC ratio were reported; 3) patients were diagnosed with gram-positive infections with well-validated diagnostic criteria. Reviews, editorials, guidelines and case reports were excluded. We also contacted the authors for related information if data provided were insufficient.

Data extraction and outcomes {#sec010}
----------------------------

All data were extracted independently by the two authors. Data extracted from the identified studies included the author (s), year of publication, country in which the study was conducted, study design, number of patients enrolled, population characteristics (type and etiology of infections), results of clinical outcomes and breakpoints of AUC~0-24~/MIC ratio. The outcomes of the review were all-cause mortality and infection treatment failure.

Quality appraisal {#sec011}
-----------------

Two authors independently assessed the quality of included studies. Discrepancies were resolved by discussion or through consultation with the third reviewer (SDZ). The potential risks of bias in RCTs were assessed according to the criteria developed using the Cochrane risk of bias tool. The quality of observational studies was assessed using the New Castle-Ottawa (NOS) scales.

Statistical analysis {#sec012}
--------------------

All statistical analyses were performed in STATA 12.0 (Stata Corp LP, College Station, TX, United States). Pooled risk ratios (RRs) and 95% confidence intervals (CIs) were calculated using the Mantel-Haenszel (M-H) fixed effects model if there was no evidence of significant heterogeneity for these outcomes, or random effects model if significant heterogeneity for these outcomes was present. Subgroup analyses were performed according to different methods for MIC determination. Heterogeneity among the studies was assessed using χ^2^ test and quantified using the Higgins I^2^\[[@pone.0146224.ref007]\]. To account for the low statistical power of the χ^2^ test for heterogeneity, P = 0.10 was considered not significant. If P\<0.10, then a sensitivity analysis was performed to assess the validity of the outcomes. Publication bias was examined by Egger's tests if there were at least five studies for each outcome\[[@pone.0146224.ref008]\]. The significance level was set at 0.05.

Methods for this systematic review were developed according to recommendations from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklists (See [S2 File](#pone.0146224.s003){ref-type="supplementary-material"} for details).

Results {#sec013}
=======

A total of 66464 were excluded from 67406 references after a review of titles: 21621 were duplicate and 44843 were not relevant to the guideline drafting. Next, we initially identified 942 potentially relevant studies using systematic database searching and 13 studies using manual searching. The full-text articles of the remaining 955 studies were evaluated. Another 938 studies were excluded because they were not relevant to this systematic review. Among the other 17 studies, 5 of the studies did not compare the clinical outcomes between the high and low AUC~0-24~/MIC ratio groups, 3 studies did not present sufficient clinical data. Nine studies were ultimately included in the meta-analysis. The flow chart of selection of studies and reasons for exclusion is presented in [Fig 1](#pone.0146224.g001){ref-type="fig"}.

![Flow chart depicting the selection process of studies included in the meta-analysis.](pone.0146224.g001){#pone.0146224.g001}

Study description {#sec014}
-----------------

Studies included in our review were all cohort studies\[[@pone.0146224.ref009]--[@pone.0146224.ref017]\]. No RCTs were retrieved. These studies included a total of 916 patients. A summary description of the included studies is reported in [Table 1](#pone.0146224.t001){ref-type="table"}. Of these studies, four studies were performed in the United States, two in Australia, and one each in Belgium, Canada, and the Republic of Korea.

10.1371/journal.pone.0146224.t001

###### Main Characteristics of Studies Included in the Meta-analysis.

![](pone.0146224.t001){#pone.0146224.t001g}

  Reference (year)                                    Study design; country                                          Number of patients   Pathogens          Type of infections                                                                                                            Male,%   Mean age(SD)
  --------------------------------------------------- -------------------------------------------------------------- -------------------- ------------------ ----------------------------------------------------------------------------------------------------------------------------- -------- --------------
  Ampe et al.(2013) \[[@pone.0146224.ref009]\]        Prospective; Belgium                                           20                   CoNS, MRSA, MSSA   Foreign body, osteomyelitis, septicaemia                                                                                      70       65.6(12.6)
  Brown et al.(2012)\[[@pone.0146224.ref010]\]        Retrospective; the United States                               44                   MRSA               Complicated bacteremia, infective endocarditis                                                                                50       54.8(16)
  Gawronski et al.(2013)\[[@pone.0146224.ref011]\]    Retrospective; the United States                               59                   MRSA               Complicated bacteria, osteomyelitis                                                                                           59       54(16)
  Ghosh et al.(2014)\[[@pone.0146224.ref012]\]        Retrospective; Australia                                       127                  MRSA               Abdominal sources, endocarditis, non-endocarditis vascular sources, pneumonia                                                 68.5     64.6(NR)
  Holmes et al.(2013)\[[@pone.0146224.ref013]\]       Prospective[^a^](#t001fn002){ref-type="table-fn"}; Australia   182                  MRSA, MSSA         Endocarditis, osteoarticular, pneumonia, sepsis syndrome, skin and soft tissue                                                70       NR
  Jung et al.(2014)\[[@pone.0146224.ref014]\]         Retrospective; the Republic of Korea                           76                   MRSA               Bone and joint, catheter-related, deep incisional/organ space, endocarditis, pneumonia, skin and soft tissue, surgical site   76.3     NR
  Kullar et al.(2011)\[[@pone.0146224.ref015]\]       Retrospective; the United States                               320                  MRSA               Bone and joint, catheter-related, deep abscess, endocarditis, multiple sites, pneumonia, skin/wound                           NR       54(NR)
  Moise et al.(2000)\[[@pone.0146224.ref016]\]        Retrospective; the United States                               53                   MRSA, MSSA         Lower respiratory tract                                                                                                       61       69.1(15)
  Zelenitsky et al.(2013)\[[@pone.0146224.ref017]\]   Retrospective; Canada                                          35                   MRSA               Bloodstream, central nervous system, endocarditis, intra-abdominal, lower respiratory tract, skin/skin structure              62.9     61.9(15.2)

CoNS, coagulase-negative *Staphylococci*; MSSA, methicillin sensitive *Staphylococcus aureus*; NR, not reported; SD, standard difference.

^a^ Additional clinical data required for analysis were collected retrospectively using a detailed chart review.

Quality of the included studies {#sec015}
-------------------------------

Quality appraisal of the included cohort studies is shown in [Table 2](#pone.0146224.t002){ref-type="table"}. Six studies completely accounted for the nine factors assessed. One study was adequate in eight of the nine factors, and two studies were adequate in seven of the nine factors.

10.1371/journal.pone.0146224.t002

###### Quality Appraisal of Observational Studies.

![](pone.0146224.t002){#pone.0146224.t002g}

  References(year)          Quality indicators                                             
  ------------------------- -------------------- ----- ----- ----- ----- ----- ----- ----- -----
  Ampe et al.(2013)         Yes                  Yes   Yes   Yes   Yes   Yes   Yes   Yes   Yes
  Brown et al.(2012)        Yes                  Yes   Yes   Yes   Yes   Yes   Yes   Yes   Yes
  Gawronski et al.(2013)    Yes                  Yes   Yes   Yes   /     /     Yes   Yes   Yes
  Ghosh et al.(2014)        Yes                  Yes   Yes   Yes   Yes   Yes   Yes   Yes   Yes
  Holmes et al.(2013)       Yes                  Yes   Yes   Yes   No    Yes   Yes   Yes   Yes
  Jung et al.(2014)         Yes                  Yes   Yes   Yes   Yes   Yes   Yes   Yes   Yes
  Kullar et al.(2011)       Yes                  Yes   Yes   Yes   Yes   Yes   Yes   Yes   Yes
  Moise et al.(2000)        Yes                  Yes   Yes   Yes   Yes   Yes   Yes   Yes   Yes
  Zelenitsky et al.(2013)   Yes                  Yes   Yes   Yes   No    No    Yes   Yes   Yes

^a^ Indicates exposed cohort truly representative.

^b^ Non-exposed cohort drawn from the same community.

^c^ Ascertainment of exposure from a secure record.

^d^ Outcome of interest not present at start of study.

^e^ Cohorts comparable on basis of site and etiology of infections, or APACHEII Score.

^f^ Cohorts comparable on other factors.

^g^ Assessment of outcome of record linkage or independent blind assessment.

^h^ Follow-ups that were sufficient for outcomes to occur.

^i^ Complete accounting for cohorts.

Outcomes {#sec016}
--------

### Mortality {#sec017}

Four studies reported all-cause mortality. There was no significant heterogeneity among these studies (p = 0.785,I^2^ = 0.0%), so a fixed effects model was used ([Fig 2](#pone.0146224.g002){ref-type="fig"}). Compared with low AUC~0-24~/MIC groups, the high AUC~0-24~/MIC groups had significantly lower mortality rates (RR = 0.47, 95%CI = 0.31--0.70, p\<0.001).

![Risk ratios of all-cause mortality rates: high versus low AUC~0-24~/MIC ratio.\
Test of all-cause mortality rates for overall effect: Z = 3.72, P\<0.001; test of all-cause mortality rates in Etest Study subgroup for overall effect: Z = 2.12, P = 0.034; test of all-cause mortality rates in BMD Study subgroup for overall effect: Z = 3.12, P = 0.002.](pone.0146224.g002){#pone.0146224.g002}

Among these studies, two studies applied the BMD method (referred to as the "BMD Study"), and the remaining studies applied the Etest method (referred to as the "Etest Study") for MIC determination. Subgroup analyses showed that in both the BMD Study and Etest Study, high AUC~0-24~/MIC groups had significantly lower mortality rates (BMD: RR = 0.49, 95%CI = 0.31--0.77, p = 0.002; Etest: RR = 0.37, 95%CI = 0.15--0.93, p = 0.034). No significant heterogeneity was found (BMD: p = 0.395, I^2^ = 0.0% and Etest: p = 0.817,I^2^ = 0.0%).

### Rate of infection treatment failure {#sec018}

Six studies reported rates of infection treatment failure. There was significant heterogeneity among these studies (p = 0.014, I^2^ = 64.7%), and thus we used a random-effect model ([Fig 3](#pone.0146224.g003){ref-type="fig"}). Compared with low AUC~0-24~/MIC groups, high AUC~0-24~/MIC groups had significantly lower rates of infection treatment failure (RR = 0.47, 95%CI = 0.30--0.73, p = 0.001). These six studies applied the BMD method to determine the MIC values.

![Risk ratios of rates of infection treatment failure: high versus low AUC~0-24~/MIC ratio.\
Test of rates of infection treatment failure for overall effect: Z = 3.34, P = 0.001.](pone.0146224.g003){#pone.0146224.g003}

### Breakpoints of the AUC~0-24~/MIC ratio {#sec019}

Among the studies included in this systematic review, seven studies applied BMD method to determine the MIC values. All breakpoints reported from these studies fell within 85% to 115% of 400, ranging from 345 to 451 (See [Table 3](#pone.0146224.t003){ref-type="table"}).

10.1371/journal.pone.0146224.t003

###### Outcomes, breakpoints of AUC~0-24~/MIC ratio and MIC determination methods of studies included in the meta-analysis.

![](pone.0146224.t003){#pone.0146224.t003g}

  Reference(year)           Outcomes available in systematic review            All-cause mortality (deaths/total)   Infection treatment failure (failures/total)   Breakpoints of AUC~0-24~/MIC ratio   MIC determination methods           
  ------------------------- -------------------------------------------------- ------------------------------------ ---------------------------------------------- ------------------------------------ --------------------------- ------- -------
  Ampe et al.(2013)         Infection treatment failure                        /                                    /                                              2/14                                 3/6                         451     BMD
  Brown et al.(2012)        All-cause mortality                                6/37                                 6/7                                            /                                    /                           211     Etest
  Gawronski et al.(2013)    All-cause mortality; Infection treatment failure   0/23                                 1/36                                           2/23                                 7/36                        293     Etest
  Ghosh et al.(2014)        Infection treatment failure                        /                                    /                                              18/77                                27/50                       398     BMD
  Holmes et al.(2013)       All-cause mortality                                17/108                               21/74                                          /                                    /                           373     BMD
  Jung et al.(2014)         Infection treatment failure                        /                                    /                                              10/52                                10/24                       398.5   BMD
  Kullar et al.(2011)       Infection treatment failure                        /                                    /                                              107/221                              61/99                       421     BMD
  Moise et al.(2000)        Infection treatment failure                        /                                    /                                              7/32                                 16/21                       345     BMD
  Zelenitsky et al.(2013)   All-cause mortality                                6/20                                 12/15                                          /                                    /                           451     BMD

Heterogeneity and publication bias {#sec020}
----------------------------------

Because there was significant heterogeneity among the studies reporting rates of infection treatment failure, we performed a sensitivity analysis (See [S1 Fig](#pone.0146224.s001){ref-type="supplementary-material"}), which showed that Kullar's study had a significant effect on the meta-analysis result. Heterogeneity was not significant after we excluded that study (I^2^ = 0.0%, p = 0.858) and results were consistent (See [Fig 4](#pone.0146224.g004){ref-type="fig"}, RR = 0.39, 95%CI = 0.28--0.55, p = 0.001).

![Risk ratios of rates of infection treatment failure: high versus low AUC~0-24~/MIC ratio (Kullar's study was excluded).\
Test of rates of infection treatment failure for overall effect: Z = 5.55, P\<0.001.](pone.0146224.g004){#pone.0146224.g004}

For rates of infection treatment failure, the amount of studies was enough to perform the Egger's test for publication bias. No significant result was observed (P = 0.706).

Discussion {#sec021}
==========

Our systematic review and meta-analysis demonstrated that high values of AUC~0-24~/MIC had significant advantages compared to low values in terms of all-cause mortality rates (reduced by 53%) and rates of infection treatment failure (reduced by 53%, coming to 61% after correcting for heterogeneity) by reaching the breakpoint of 400. To the best of our knowledge, this report describes the first systematic review to support this hypothesis. Our research has raised the grade of evidence concerning this issue, which may be beneficial for clinicians, clinical pharmacists and future therapeutic drug monitoring guideline writers.

Kullar's study was excluded from meta-analysis because of its significant effect on heterogeneity. The possible reason of the effect was that patients among the cohort had relatively higher baseline APACHE-II scores.

Importantly, the apparent values of AUC~0-24~/ MIC ratio vary depending on different MIC determination methods. Commonly applied methods include the BMD and Etest methods. Latter results are consistently 0.5 to 1.5 times higher than the former results after log2 conversion\[[@pone.0146224.ref018],[@pone.0146224.ref019]\]. A target value of 400 recommended by the American guideline was based on results obtained from BMD method\[[@pone.0146224.ref006]\]. Among the studies included in this meta-analysis, 7 studies applied BMD method. Breakpoints of the AUC~0-24~/MIC ratio were entirely within the range of 85--115% of 400. In addition, because the breakpoints were calculated using a fine classification and regression tree (CART) algorithm and a margin of error may exists, there will be slight differences. Different infection sites and pathogens may also cause the variations, although apparent associations were difficult to be found based on included studies. Our study had confirmed the target AUC~0-24~/MIC value of 400.

Two studies reported 211 and 293 as breakpoints respectively. The Etest method was applied for MIC determination, which probably accounting for the lower values. Holmes *et al*.\[[@pone.0146224.ref013]\] had performed a linear regression analysis and found that the target of 400 (based on BMD method) was equivalent to 226 based on the Etest method, which was very close to 211. This provided evidence for our analysis.

Pharmacokinetic and pharmacodynamics reviews have recommended the AUC~0-24~/MIC ratio as the preferred parameter partly based on data obtained from animal models, *in vitro* studies and limited human studies\[[@pone.0146224.ref020]--[@pone.0146224.ref023]\]. Moise-Broder *et al*. explored the use of AUC~0-24~/MIC ratio in predicting clinical and microbiological success in the treatment of ventilator-associated *S*. *aureus* pneumonia. An AUC~0-24~/MIC ratio of ≥ 400 was advocated as a target to achieve clinical success with vancomycin\[[@pone.0146224.ref006]\]. On the basis of these studies, the vancomycin TDM guideline (published in 2009) developed by American Society of Hospital-System Pharmacists recommended 400 as a clinically target, which requiring further support from solid evidence-based research.

However, there are some deficiencies in this study. First, a relatively small number of studies were included, which were all observational ones. Second, there was significant heterogeneity among the six studies, which reported the rate of infection treatment failure. After we found and excluded the questionable study, the problem was resolved and meta-analysis results were consistent.

This study focused on the relevant predictors of vancomycin clinical effectiveness. At the present, researches on the association between vancomycin AUC~0-24~/ MIC and safety are limited. Some studies showed that high ratio values may increase the incidence of nephrotoxicity\[[@pone.0146224.ref018]\]. Neely *et al*.\[[@pone.0146224.ref024]\] discovered that when the AUC~0-24~/ MIC ratio was higher than 700, the incidence of nephrotoxicity was significantly increased, based on a population model. Lodise *et al*. \[[@pone.0146224.ref025]\] found that in 27 patients whose AUC~0-24~/ MIC values were equal to or higher than 1300, 26% had developed nephrotoxicity. Additional studies on nephrotoxicity are needed in the future.

In conclusion, this report describes the first systematic review indicating that achieving a high AUC~0-24~/MIC ratio of vancomycin could significantly decrease mortality rates by 53% and rates of infection treatment failure by 61%, with 400 being a reasonable target.
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